Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | TPMT | P51580 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483431 | 0.86 | HTT (0.62) | CA12CA1CA2CA4CA6 | |
| SCHEMBL10603367 | 0.84 | SLC6A4 (0.63) | CA12CA1CA2CA4CA6 | |
| SCHEMBL20543172 | 0.82 | TSHR (0.58) | CA12CA1CA2CA4CA6 | |
| SCHEMBL11661009 | 0.82 | MAPK1 (0.55) | TPMTMAPK1MEN1KMT2AGAA | |
| SCHEMBL22060049 | 0.82 | TSHR (0.58) | CA12CA1CA2CA4CA6 | |
| SCHEMBL7798981 | 0.81 | TSHR (0.56) | CA12CA1CA2CA4CA6 | |
| SCHEMBL29191638 | 0.81 | TSHR (0.56) | CA12CA1CA2CA4CA6 | |
| SCHEMBL9188659 | 0.79 | CTNNB1 (0.55) | CA12CA1CA2CA4CA6 | |
| SCHEMBL6155139 | 0.78 | TSHR (0.53) | CA12CA1CA2CA4CA6 | |
| SCHEMBL11522245 | 0.78 | KDM4E (0.61) | TSHRCYP1A2CYP2C19LDHAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901116-B2 | Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-12-02 | — | — | US | disclosed |
| US-20140088095-A1 | METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-03-27 | — | — | US | disclosed |
| US-8541409-B2 | Carbamoyloxy arylalkanoyl arylpiperazine analgesics | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-09-24 | — | — | US | disclosed |
| EP-2155736-B1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO LTD (KR) | 2011-12-21 | — | — | EP | disclosed |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-08-11 | — | — | US | disclosed |
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO. LTD. (KR) | 2010-06-24 | — | — | US | disclosed |
| EP-2155736-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK Holdings Co., Ltd. (KR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008140198-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO., LTD. (KR) | 2008-11-20 | — | — | WO | disclosed |
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | disclosed |
| EP-1119567-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | HTR5A, OPRD1, OPRL1 | CA12 3936/4885CA1 2664/4885CA2 1008/4885 |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | HTR5A, CNR2, CNR1 | CA12 3608/4885CA1 2157/4885CA2 971/4885 |
| US-20140088095-A1 | METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND | HTR5A, OPRL1, HDAC3 | CA12 2996/4885CA1 1277/4885CA2 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.